Who is sponsoring NCT05278871?

NCT05278871 is sponsored by Microelastic Ultrasound Systems Inc.

What drugs are being tested in NCT05278871?

Interventions in NCT05278871: Constructive Shearwave Interference (CSI).

What condition does NCT05278871 study?

NCT05278871 studies Lymphedema of Upper Arm, Breast Cancer.

Is NCT05278871 still recruiting?

NCT05278871 is currently completed. Last updated 13 December 2023.

Last reviewed 2023-12-13 · How we verify

NCT05278871

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Noninvasive Assessment of Lymphedema Among Breast Cancer Survivors

Completed NA Last updated 13 December 2023

What this trial tests

NA trial testing Constructive Shearwave Interference (CSI) in Lymphedema of Upper Arm in 21 participants. Completed in 31 August 2023.

Timeline

26 May 2022

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	Microelastic Ultrasound Systems Inc
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	21
Start date	26 May 2022
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	2 locations across United States

Drugs / interventions tested

Constructive Shearwave Interference (CSI)

Conditions studied

Lymphedema of Upper Arm — all drugs for Lymphedema of Upper Arm →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

Microelastic Ultrasound Systems Inc

Who can join

18 and older, any sex, with Lymphedema of Upper Arm or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This proof of concept study will evaluate the ability of a new, ultrasound based technology called Bullseye Constructive Shearwave Interference (CSI) (trade name, Bullseye Elasticity Quantification) to measure lymphedema of the upper arm among breast cancer survivors. The study's hypothesis is that the CSI device can detect the presence of clinically significant lymphedema when compared with the standard arm tape measurement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lymphedema of Upper Arm

Currently open trials in the same condition.

NCT06144164 — A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With B · Phase 3 · recruiting
NCT05203835 — Trial of Acebilustat for the Treatment of Upper Arm Lymphedema · Phase 2 · active not recruiting
NCT05142800 — Screening For BCRL In Targeted Therapy For Breast Cancer · active not recruiting
NCT06532955 — The Robot-LVA Study: Robot-assisted Microsurgical Lymphaticovenous Anastomosis in Breast Cancer-related Lymphedema · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05278871 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Microelastic Ultrasound Systems Inc
Last refreshed: 13 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05278871.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing